0001209191-23-053395.txt : 20231023
0001209191-23-053395.hdr.sgml : 20231023
20231023202301
ACCESSION NUMBER: 0001209191-23-053395
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231019
FILED AS OF DATE: 20231023
DATE AS OF CHANGE: 20231023
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Jones Susan Dana
CENTRAL INDEX KEY: 0001995339
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40384
FILM NUMBER: 231340894
MAIL ADDRESS:
STREET 1: C/O TOURMALINE BIO, INC.
STREET 2: 27 WEST 24TH STREET, SUITE 702
CITY: NEW YORK
STATE: NY
ZIP: 10010
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Tourmaline Bio, Inc.
CENTRAL INDEX KEY: 0001827506
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 27 WEST 24TH STREET
STREET 2: SUITE 702
CITY: NEW YORK
STATE: NY
ZIP: 10010
BUSINESS PHONE: 646-481-9832
MAIL ADDRESS:
STREET 1: 27 WEST 24TH STREET
STREET 2: SUITE 702
CITY: NEW YORK
STATE: NY
ZIP: 10010
FORMER COMPANY:
FORMER CONFORMED NAME: Talaris Therapeutics, Inc.
DATE OF NAME CHANGE: 20201007
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-10-19
0
0001827506
Tourmaline Bio, Inc.
TRML
0001995339
Jones Susan Dana
C/O TOURMALINE BIO, INC.
27 WEST 24TH STREET, SUITE 702
NEW YORK
NY
10010
0
1
0
0
Chief Technology Officer
0
Common Stock
2023-10-19
4
A
0
22934
A
22934
D
Employee Stock Option (Right to Buy)
7.90
2023-10-19
4
A
0
76219
A
2033-06-17
Common Stock
76219
76219
D
Employee Stock Option (Right to Buy)
9.46
2023-10-23
4
A
0
46774
0.00
A
2033-10-23
Common Stock
46774
46774
D
12,630 of these shares are subject to a repurchase option in favor of the Issuer in the event that the Reporting Person's continuous service is terminated. Such repurchase option shall lapse in equal monthly installments until such shares are fully vested on June 1, 2026.
Received in exchange for 287,500 shares of common stock of Tourmaline Bio, Inc. ("Tourmaline") pursuant to an Agreement and Plan of Merger dated as of June 22, 2023 (the "Merger Agreement") by and among Tourmaline, the Issuer and Terrain Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on October 19, 2023, Merger Sub merged with and into Tourmaline (the "Merger"), with Tourmaline surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Tourmaline common stock was converted into the right to receive 0.07977 of a share of the Issuer's common stock, after giving effect to a reverse stock split of the Issuer's common stock of 10-for-1. Subsequent to the Merger, the name of the Issuer was changed from Talaris Therapeutics, Inc. to Tourmaline Bio, Inc.
Upon the closing of the Merger, each outstanding option to purchase shares of Tourmaline common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tourmaline stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split.
The shares subject to the option vest as to 25% of the shares on June 14, 2024 with the remainder vesting in the following 36 equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.
Received in exchange for a stock option to acquire 955,500 shares of Tourmaline common stock pursuant to the Merger Agreement.
The shares subject to the option vest as to 25% of the shares on October 23, 2024 with the remainder vesting in the following 36 equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.
/s/ Brad Middlekauff, Attorney-in-Fact
2023-10-23